Pfizer's Velsipity Receives EU Marketing Authorization for Moderate-to-Severe Ulcerative Colitis
EU Marketing Authorization and Target Patients
The European Union authorized Pfizer Inc. (PFE)'s Velsipity (active ingredient: etrasimod) on February 16, 2024, for the treatment of moderate-to-severe active ulcerative colitis. The target population includes patients aged 16 years and older who have had an inadequate response to, lost response to, or are intolerant of existing therapies or biologics. The recommended dose is 2mg tablets once daily. Following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on December 14, 2023, the product is now marketed. The next key step for revenue conversion is reimbursement and pricing negotiations in EU member states.
Selective S1P Modulation Mechanism
Etrasimod selectively modulates sphingosine-1-phosphate receptors 1, 4, and 5 (S1P1, S1P4, S1P5), partially and reversibly inhibiting lymphocyte migration from lymph nodes to the bloodstream and intestinal tissue. Unlike biologics that require injection or infusion, etrasimod is a fixed-dose oral medication, offering dosing convenience and does not require dose titration. However, risks such as infection, bradycardia, conduction disorders, liver impairment, macular edema, and elevated blood pressure are class-related, and patient selection and post-marketing safety monitoring will influence the pace of prescription adoption.
Clinical Evidence
The approval is based on two Phase 3 trials, ELEVATE UC 52 and ELEVATE UC 12, involving a total of 743 patients. In ELEVATE UC 52, the clinical remission rate was 27.0% for Velsipity versus 7.0% for placebo at 12 weeks and 32.0% versus 7.0% at 52 weeks, with p<0.001 at both time points. In ELEVATE UC 12, the 12-week remission rate was 26.0% versus 15.0%, also statistically significant. The EMA's integrated analysis showed a 12-week mucosal healing rate of 19% versus 7%, supporting both symptom control and endoscopic and histological improvement.
Regulatory History and Competitive Landscape
The U.S. Food and Drug Administration (FDA) approved Velsipity for adult patients on October 12, 2023, without referring it to an advisory committee (AdComm) due to the absence of unexpected major safety or efficacy concerns. In Japan, manufacturing and marketing authorization was granted on June 24, 2025, for patients with moderate-to-severe ulcerative colitis who have had an inadequate response to existing therapies, securing regulatory approval in the U.S., EU, and Japan. Competitors include Zeposia (ozanimod, S1P1/S1P5; Bristol Myers Squibb), Rinvoq (upadacitinib, JAK1 inhibitor; AbbVie), and Entyvio (vedolizumab, Ξ±4Ξ²7 integrin antibody; Takeda). Efficacy, safety warnings, dosing convenience, and reimbursement conditions are key factors influencing prescribing decisions.
Global ulcerative colitis treatment revenue reached approximately USD 7.8 billion in 2023 and is projected to expand to USD 13.2 billion by 2030, making Velsipity's EU authorization a new commercial growth driver for Pfizer Inc. (PFE). The 52-week remission rate of 32.0% versus 7.0% in the Phase 3 ELEVATE UC 52 trial supports long-term efficacy, although it is not a direct comparison with Zeposia, Rinvoq, or Entyvio. In the short term, reimbursement and pricing in individual countries and adoption rates among specialists will determine revenue speed. In the medium to long term, the once-daily oral administration may erode the market share of injectable or infusion therapies. For researchers, long-term data on the impact of S1P1/4/5 selectivity on clinical safety and sustained remission are critical. For the industry, the approval of an oral immunomodulator that complements the regulatory limitations of JAK inhibitors signifies intensified competition. Approval in the U.S., EU, and Japan, along with the FDA's decision not to refer to AdComm, reduces regulatory risk, but post-marketing safety monitoring for infections, cardiovascular, ophthalmic, and liver safety remains ongoing.
Source: EMA (ema)